Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
Pulmonary hypertension is characterized by an increase in the pressures in the blood supply to the lungs greater than a mean pressure of 25mmHg and a concomitant increase in overall pulmonary vascular resistance (PVR).
- Trial name
- NCT02734953
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Pulmonary Arterial Hypertension
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension
Previously characterised PAH patients, including idiopathic, heritable and other forms of group 1 PAH with and without BMPR2 mutation which have already been analysed and are regularly seen in the Center for Pulmonary…
- Trial name
- AMIA (NCT04086537)
- Testing
- hepcidin levels and BMPR2 expression
- Where
- Germany
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Pulmonary Artery Hypertension
Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
The aim of the study is that evaluation of basic and accessory respiratory muscles and their relationship of six minute walk test in patient with pulmonary arterial hypertension (PAH)
- Trial name
- NCT05056532
- Testing
- patient assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Giresun University
Pulmonary Arterial Hypertension
A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary…
- Trial name
- NCT06603285
- Testing
- Treprostinil
- Volunteers
- 20 people
- Sponsor
- Excelsior
Hypertension, Pulmonary
Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
The safety and efficacy at 100 mg once daily for oral dose of sitaxentan sodium were demonstrated in the STRIDE clinical trial program. Sitaxentan sodium was approved in the EU, Canada and Australia.
- Trial name
- NCT01210443
- Testing
- Sitaxentan
- Where
- 2 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
Sitaxsentan has a low drug-drug interaction potential and it did not have a clinically relevant effect on pharmacokinetics of sildenafil (a CYP3A sensitive substrate and PDE5 inhibitor).
- Trial name
- NCT01244620
- Testing
- sitaxentan, tadalafil, sitaxsentan
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH.
- Trial name
- ViTAL-PH (NCT06846554)
- Testing
- APL-9796
- Where
- 6 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Apollo Therapeutics Ltd
Rare Diseases, Amyloidosis
Institutional Registry of Rare Diseases
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).
- Conditions
- Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis
- Trial name
- NCT06573723
- Where
- Argentina
- Volunteers
- 380 people
- Sponsor
- Hospital Italiano de Buenos Aires
Pulmonary Arterial Hypertension
Treprostinil Combined With Tadalafil for Pulmonary Hypertension
Objectives: To test whether the combined administration of the medications treprostinil(a prostacycline therapy), and tadalafil(a PDE-5 [ phosphodiesterase type 5]Inhibitor therapy) is better than the administration of…
- Trial name
- T2 (NCT01302444)
- Testing
- Tadalafil
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- Rhode Island Hospital
Pulmonary Arterial Hypertension
Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH
The development of disease-targeted medication for the treatment of pulmonary arterial hypertension (PAH) has significantly improved within the last years, leading to the development of 10 approved agents.
- Trial name
- EPIC (NCT02484807)
- Testing
- no intervention, only observation of different groups
- Where
- Germany
- Volunteers
- 125 people
- Sponsor
- Heidelberg University
Pulmonary Arterial Hypertension
Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
The AIR001-CS05 study evaluated the safety and efficacy (effectiveness) of AIR001 over 16 weeks in subjects who have PAH. The purpose of the AIR001-CS06 study is to evaluate the intermediate / long-term safety of AIR001 in…
- Trial name
- NCT01725269
- Testing
- AIR001
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 17 people
- Sponsor
- Aires Pharmaceuticals, Inc.
Sleep Disorders
Screening for Sleep Hypoxemia in Pulmonary Arterial Hypertension
In the investigators study, and regarding results of small cohorts in the literature, the investigators hypothesize that hypoxemia is frequent in IPAH and CPEPH.
- Trial name
- Sommeil_HTAP (NCT01371669)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy…
- Trial name
- TripleTRE (NCT06317805)
- Testing
- Generic treprostinil sodium + Standard of Care (Double Oral), Standard of Care - Double Oral
- Where
- 28 sites in Argentina, Austria and 10 more
- Volunteers
- 110 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart.
- Trial name
- SOTERIA (NCT07218029)
- Testing
- Sotatercept
- Where
- 137 sites in United States, Argentina and 25 more
- Volunteers
- 815 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
An Investigator initiated trial (IIT) using a prospective, randomized, double-blind, parallel group, placebo-controlled, clinical study design.
- Trial name
- TAPE (NCT04972656)
- Testing
- Ambrisentan
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects
This is a four-part study of the safety, tolerability, and PK profile of sodium nitrite inhalation solution (AIR001) of ascending multiple doses (Part A) and of escalating doses with steady-state sildenafil (Part B) to healthy…
- Trial name
- NCT01409122
- Testing
- 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Aires Pharmaceuticals, Inc.
Associated Pulmonary Arterial Hypertension
To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis
The study will be carried out on 50 consecutive consenting patients of systemic sclerosis with PAH recruited from outpatient department of internal medicine and rheumatology clinic of PGIMER, Chandigarh, India It is a single…
- Trial name
- BosSilSS (NCT03053739)
- Testing
- Sildenafil 20mg and Bosentan 62.5mg
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Incorporating the Venous Excess Ultrasound Score (VExUS Score) Into Contemporary Haemodynamic Risk Assessment in Pulmonary Arterial Hypertension: The INVEXUS-PAH Study
This prospective observational study aims to evaluate the relationship between the Venous Excess Ultrasound Score (VEXUS) and the ESC/ERS 2022 simplified four-strata risk assessment model in adult patients with World Health…
- Trial name
- INVEXUS-PAH (NCT07266012)
- Where
- Turkey (Türkiye)
- Volunteers
- 86 people
- Sponsor
- Istanbul University - Cerrahpasa
Pulmonary Hypertension
Inspiratory Muscle Training in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a rare condition characterised by high blood pressure in the lungs and results in breathlessness and reduced exercise capacity for patients.
- Trial name
- NCT04197388
- Testing
- Inspiratory muscle training device
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Golden Jubilee National Hospital
Pulmonary Arterial Hypertension
Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension
The objective of this randomized control trial is to gain clinical insight on the use of pulmonary artery denervation (PADN) for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- PADN-CFDA (NCT03282266)
- Testing
- PADN
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University